Monday February 1, 5:47 pm Eastern Time
Company Press Release
SOURCE: Isis Pharmaceuticals
Isis Announces Organizational Changes
CARLSBAD, Calif., Feb. 1 /PRNewswire/ -- Dr. Daniel Kisner, President and Chief Operating Officer of Isis Pharmaceuticals (Nasdaq: ISIP - news) has resigned to assume the position of Chief Executive Officer of Caliper Technologies. Dr. Kisner will leave Isis and assume his new position on March 1, 1999.
''Dr. Kisner has made substantial contributions to Isis during his eight years with us. The opportunity to be C.E.O. at Caliper Technologies is exceptional. All of us at Isis wish Dan well. With Dan's help, we have built an organization of exceptional people with real depth and we believe that this will be a smooth transition,'' said Dr. Stanley T. Crooke, Chairman and CEO of Isis.
This press release contains forward-looking statements pertaining to Isis' management. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Actual results could differ materially from those projected in this release. As a result, the reader is cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' management are described in additional detail in Isis' Annual Report on Form 10-K for the year ended December 31, 1997 which is on file with the U.S. Securities Exchange Commission, copies of which are available from the company.
Isis Pharmaceuticals, based in northern San Diego County, is engaged in the discovery and development of novel human therapeutic compounds. Isis has six compounds in human clinical trials: Vitravene(TM) (fomivirsen), to treat CMV-induced retinitis in AIDS patients, has been approved for marketing by the FDA and is currently undergoing regulatory review in Europe; ISIS 2302, an inhibitor of ICAM-1, is in a pivotal quality trial for Crohn's disease, Phase II clinical trials for renal transplant rejection, rheumatoid arthritis and ulcerative colitis, and is being explored as a topical administration for psoriasis and an aerosol administration for asthma; ISIS 3521 is in Phase II trials as a treatment for cancer; ISIS 5132 is in Phase II clinical trials as a treatment for cancer; ISIS 2503 is in Phase I trials as a treatment for cancer; and ISIS 13312 is in Phase I/II clinical trials for the treatment of CMV retinitis in AIDS patients. The company also has several additional compounds in preclinical development. Isis' broad medicinal chemistry and biology research programs support efforts in both antisense and small molecule drug discovery.
Vitravene(TM) is a trademark of Novartis AG. |
